Efficacy and safety of Arzerra in patients with Fludarabine and Alemtuzumab-refractory chronic lymphocytic leukemia


GlaxoSmithKline ( GSK ) and Genmab have announced the results from the concluded pivotal trial of Ofatumumab ( Arzerra ) in patients with Fludarabine ( Fludara ) and Alemtuzumab ( Campath ) refractory chronic lymphocytic leukemia.

Ofatumumab was given accelerated approval by the FDA ( Food and Drug Administration ) on October 26, 2009 for the treatment of patients with chronic lymphocytic leukemia who are refractory to Fludarabine and Alemtuzumab treatment based on the interim results from this trial in 59 patients. On April 19, 2010, the European Commission granted a conditional marketing authorization to Arzerra for the treatment of chronic lymphocytic leukaemia in patients who are refractory to Fludarabine and Alemtuzumab.

A total of 95 patients with Fludarabine and Alemtuzumab refractory chronic lymphocytic leukemia were treated in the study. The objective response rate ( ORR ), as determined by an Independent Review Committee, in the study was 51%. In addition to the 95 patients in the efficacy analysis the study also included 128 patients with relapsed or refractory chronic lymphocytic leukemia, who were not refractory to both Fludarabine and Alemtuzumab.

There were no unexpected safety findings reported with the total study population ( n=223 ). The most common adverse reactions ( greater than or equal to 10% ) occurring in patients treated with Arzerra were pyrexia ( 21% ), anemia ( 18% ), diarrhea ( 17% ), neutropenia, fatigue ( 16% ), dyspnea ( 15% ), pneumonia ( 15% ), chills ( 13% ), rash ( 13% ), nausea ( 13% ), bronchitis ( 12% ), peripheral edema ( 11% ), back pain ( 10% ) and upper respiratory tract infection ( 10% ).

Results from this concluded pivotal trial are consistent with the efficacy and safety data reported in the interim analysis and demonstrate the activity of single-agent Ofatumumab in patients with heavily pretreated Fludarabine and Alemtuzumab-refractory chronic lymphocytic leukemia.

Ofatumumab is a human monoclonal antibody. Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes ( pre-B- to mature B-lymphocytes ) and on B-cell CLL. In vitro data suggest that possible mechanisms of cell lysis include complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Source: Genmab, 2010

XagenaMedicine_2010



Indietro

Altri articoli

There are increasing data that delaying starting disease-modifying drugs and/or routinely stopping all disease-modifying drugs prepregnancy or immediately postconception is...


Natalizumab ( Tysabri ), a humanized monoclonal antibody, was approved by the Food and Drug Administration ( FDA ) in...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more...


The FDA ( Food and Drug Administration ) has approved Lemtrada ( Alemtuzumab ) for the treatment of patients with...


New magnetic resonance imaging ( MRI ) data from the Lemtrada ( Alemtuzumab ) clinical development program were presented at...


Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented...


Alemtuzumab ( Lemtrada ), an anti-CD52 monoclonal antibody, has increased the risk of thyroid dysfunction in CAMMS223, a phase 2...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...


More than 80% of individuals with multiple sclerosis ( MS ) experience a relapsing-remitting disease course. Approximately 10 years after...


The results from the Lemtrada ( Alemtuzumab ) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple...